Does the media prefer NKTR or NVCT?

In the previous week, Nektar Therapeutics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 9 mentions for Nektar Therapeutics and 6 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.95 beat Nektar Therapeutics' score of 0.77 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AMLX or NVCT more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -52.92% -48.53% Nuvectis Pharma N/A -184.25% -105.24%

Does the media prefer AMLX or NVCT?

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Nuvectis Pharma. MarketBeat recorded 12 mentions for Amylyx Pharmaceuticals and 6 mentions for Nuvectis Pharma. Amylyx Pharmaceuticals' average media sentiment score of 1.45 beat Nuvectis Pharma's score of 0.95 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, NVCT or CDNA?

CareDx has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A CareDx $379.80M 6.78 -$21.35M $2.07 24.05

Is NVCT or CDNA more profitable?

CareDx has a net margin of 24.23% compared to Nuvectis Pharma's net margin of 0.00%. CareDx's return on equity of 2.87% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% CareDx 24.23% 2.87% 2.17%

Does the media refer more to NVCT or CDNA?

In the previous week, CareDx had 8 more articles in the media than Nuvectis Pharma. MarketBeat recorded 14 mentions for CareDx and 6 mentions for Nuvectis Pharma. CareDx's average media sentiment score of 1.29 beat Nuvectis Pharma's score of 0.95 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PGEN or NVCT more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -183.98% 423.75% 84.39% Nuvectis Pharma N/A -184.25% -105.24%

Does the media prefer PGEN or NVCT?

In the previous week, Precigen had 13 more articles in the media than Nuvectis Pharma. MarketBeat recorded 19 mentions for Precigen and 6 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.95 beat Precigen's score of 0.76 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 10 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NVCT or KLRA?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Is NVCT or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% Kailera Therapeutics N/A N/A N/A

Does the media refer more to NVCT or KLRA?

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 6 articles in the media. Nuvectis Pharma's average media sentiment score of 0.95 beat Kailera Therapeutics' score of 0.14 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Nuvectis Pharma (NVCT) Competitors

$23.73 -1.46 (-5.80%)

As of 08/28/2026 04:00 PM Eastern

Compare

NVCT vs. NKTR, AMLX, CDNA, PGEN, and KLRA

Should you buy Nuvectis Pharma stock or one of its competitors? Nuvectis Pharma's main competitors and comparable companies include Nektar Therapeutics (NKTR), Amylyx Pharmaceuticals (AMLX), CareDx (CDNA), Precigen (PGEN), and Kailera Therapeutics (KLRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvectis Pharma compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nektar Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Nektar Therapeutics presently has a consensus price target of $141.50, indicating a potential upside of 95.12%. Nuvectis Pharma has a consensus price target of $35.00, indicating a potential upside of 47.49%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Nektar Therapeutics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 9 mentions for Nektar Therapeutics and 6 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.95 beat Nektar Therapeutics' score of 0.77 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Nuvectis Pharma has lower revenue, but higher earnings than Nektar Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	44.83	-$164.08M	-$6.70	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Summary

Nektar Therapeutics beats Nuvectis Pharma on 10 of the 16 factors compared between the two stocks.

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Nuvectis Pharma. MarketBeat recorded 12 mentions for Amylyx Pharmaceuticals and 6 mentions for Nuvectis Pharma. Amylyx Pharmaceuticals' average media sentiment score of 1.45 beat Nuvectis Pharma's score of 0.95 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	44.30	-$144.74M	-$1.43	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Amylyx Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

Amylyx Pharmaceuticals' return on equity of -52.92% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Amylyx Pharmaceuticals currently has a consensus price target of $36.50, suggesting a potential upside of 5.07%. Nuvectis Pharma has a consensus price target of $35.00, suggesting a potential upside of 47.49%. Given Nuvectis Pharma's higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Amylyx Pharmaceuticals beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to CareDx?

Nuvectis Pharma (NASDAQ:NVCT) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Nuvectis Pharma has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, CareDx has a beta of 2.39, meaning that its stock price is 139% more volatile than the broader market.

CareDx has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
CareDx	$379.80M	6.78	-$21.35M	$2.07	24.05

In the previous week, CareDx had 8 more articles in the media than Nuvectis Pharma. MarketBeat recorded 14 mentions for CareDx and 6 mentions for Nuvectis Pharma. CareDx's average media sentiment score of 1.29 beat Nuvectis Pharma's score of 0.95 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma presently has a consensus target price of $35.00, indicating a potential upside of 47.49%. CareDx has a consensus target price of $47.75, indicating a potential downside of 4.10%. Given Nuvectis Pharma's higher probable upside, equities research analysts plainly believe Nuvectis Pharma is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CareDx	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

CareDx has a net margin of 24.23% compared to Nuvectis Pharma's net margin of 0.00%. CareDx's return on equity of 2.87% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
CareDx	24.23%	2.87%	2.17%

96.8% of Nuvectis Pharma shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 2.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

CareDx beats Nuvectis Pharma on 12 of the 16 factors compared between the two stocks.

How does Nuvectis Pharma compare to Precigen?

Precigen (NASDAQ:PGEN) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Precigen had 13 more articles in the media than Nuvectis Pharma. MarketBeat recorded 19 mentions for Precigen and 6 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.95 beat Precigen's score of 0.76 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	10 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Nuvectis Pharma	N/A	-184.25%	-105.24%

33.5% of Precigen shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Precigen presently has a consensus price target of $14.50, suggesting a potential upside of 108.63%. Nuvectis Pharma has a consensus price target of $35.00, suggesting a potential upside of 47.49%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nuvectis Pharma has lower revenue, but higher earnings than Precigen. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	255.97	-$250.64M	-$1.04	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Summary

Precigen beats Nuvectis Pharma on 11 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to Kailera Therapeutics?

Nuvectis Pharma (NASDAQ:NVCT) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

96.8% of Nuvectis Pharma shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 6 articles in the media. Nuvectis Pharma's average media sentiment score of 0.95 beat Kailera Therapeutics' score of 0.14 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Nuvectis Pharma presently has a consensus price target of $35.00, suggesting a potential upside of 47.49%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 163.73%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kailera Therapeutics' return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Kailera Therapeutics	N/A	N/A	N/A

Summary

Kailera Therapeutics beats Nuvectis Pharma on 7 of the 12 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCT vs. The Competition

Export

Metric	Nuvectis Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$774.64M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-18.11	11.62	273.16	25.45
Price / Sales	N/A	1,295.47	604.43	75.83
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	84.75	16.53	12.98	6.14
Net Income	-$26.44M	-$22.80M	$3.48B	$348.86M
7 Day Performance	0.72%	-0.31%	0.13%	-0.80%
1 Month Performance	4.26%	9.80%	7.08%	4.13%
1 Year Performance	261.74%	55.66%	24.67%	15.17%

Nuvectis Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCT Nuvectis Pharma	3.5533 of 5 stars	$23.73 -5.8%	$35.00 +47.5%	+261.7%	$774.64M	N/A	N/A	8
NKTR Nektar Therapeutics	2.3312 of 5 stars	$73.64 +1.3%	$150.00 +103.7%	+142.9%	$2.47B	$55.23M	N/A	220
AMLX Amylyx Pharmaceuticals	2.3291 of 5 stars	$35.11 +63.8%	$30.25 -13.8%	+270.4%	$2.39B	N/A	N/A	200	Positive News Analyst Forecast High Trading Volume
CDNA CareDx	3.339 of 5 stars	$46.18 -0.4%	$47.75 +3.4%	+264.5%	$2.34B	$379.80M	22.31	740	News Coverage Positive News
PGEN Precigen	3.8913 of 5 stars	$6.75 +3.1%	$14.50 +114.8%	+54.1%	$2.34B	$85.72M	N/A	190	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvectis Pharma (NVCT) Competitors

NVCT vs. NKTR, AMLX, CDNA, PGEN, and KLRA

How does Nuvectis Pharma compare to Nektar Therapeutics?

Summary

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Summary

How does Nuvectis Pharma compare to CareDx?

Summary

How does Nuvectis Pharma compare to Precigen?

Summary

How does Nuvectis Pharma compare to Kailera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvectis Pharma (NVCT) Competitors

NVCT vs. NKTR, AMLX, CDNA, PGEN, and KLRA

How does Nuvectis Pharma compare to Nektar Therapeutics?

Do insiders and institutionals believe in NKTR or NVCT?

Which has more volatility & risk, NKTR or NVCT?

Do analysts recommend NKTR or NVCT?

Does the media prefer NKTR or NVCT?

Is NKTR or NVCT more profitable?

Which has better valuation & earnings, NKTR or NVCT?

Summary

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Do institutionals and insiders hold more shares of AMLX or NVCT?

Does the media prefer AMLX or NVCT?

Which has preferable valuation & earnings, AMLX or NVCT?

Which has more volatility and risk, AMLX or NVCT?

Is AMLX or NVCT more profitable?

Do analysts recommend AMLX or NVCT?

Summary

How does Nuvectis Pharma compare to CareDx?

Which has more risk & volatility, NVCT or CDNA?

Which has higher valuation & earnings, NVCT or CDNA?

Does the media refer more to NVCT or CDNA?

Do analysts recommend NVCT or CDNA?

Is NVCT or CDNA more profitable?

Do institutionals & insiders have more ownership in NVCT or CDNA?

Summary

How does Nuvectis Pharma compare to Precigen?

Does the media prefer PGEN or NVCT?

Which has more risk & volatility, PGEN or NVCT?

Is PGEN or NVCT more profitable?

Do insiders & institutionals have more ownership in PGEN or NVCT?

Do analysts rate PGEN or NVCT?

Which has stronger valuation & earnings, PGEN or NVCT?

Summary

How does Nuvectis Pharma compare to Kailera Therapeutics?

Which has stronger earnings & valuation, NVCT or KLRA?

Do institutionals & insiders hold more shares of NVCT or KLRA?

Does the media refer more to NVCT or KLRA?

Do analysts rate NVCT or KLRA?

Is NVCT or KLRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools